Breast cancer
Conditions
Interventions
The control group:The treatment protocol comprised proton pump inhibitors (PPIs) and gastric mucosal protective agents combined with either dual therapy (5-HT3 receptor antagonists plus glucocorticoid
The experimental group:The therapeutic regimen consisted of proton pump inhibitors (PPIs) and gastric mucosal protective agents, combined with either dual antiemetic therapy (5-HT3 receptor antagonist
Sponsors
Yanwei Wang
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Diagnostic Criteria: Patients were recruited according to the following diagnostic standards: 1. Breast Cancer Diagnosis:Based on the Chinese Anti-Cancer Association Breast Cancer Professional Committee and Chinese Society of Oncology Breast Cancer Group's *Chinese Anti-Cancer Association Guidelines and Standards for Breast Cancer Diagnosis and Treatment (2024 Edition)* [China Oncology. 2023;33(12):1092-1187]. 2. "Liver Depression and Spleen Deficiency" Syndrome Differentiation (TCM Pattern Diagnosis): Patients were required to meet the diagnostic criteria for "Liver Qi Stagnation and Spleen Deficiency" syndrome as defined in the Guidelines for Integrated Traditional Chinese and Western Medicine in Breast Cancer [Beijing Journal of Traditional Chinese Medicine. 2024;43(01):7-16]. Diagnostic Requirements: (1)Primary Symptoms (must present with =3): 1) Hypochondriac distension or pain 2) Emotional depression 3) Abdominal distension 4) Loose stools or constipation (2)Secondary Symptoms (must present with 1-2): 1) Distending pain in chest and hypochondrium 2) Frequent sighing 3) Irritability or tendency to anger 4) Poor appetite 5) Borborygmus or excessive flatulence 6) Abdominal pain relieved by bowel movement 7) Alternating diarrhea and constipation (1) Meeting the aforementioned diagnostic criteria; (2) Female aged 18-70 years; (3) No other traditional Chinese medicine drug treatments were administered; (4) Eligible to participate in this trial as assessed by relevant clinical specialists; (5) Voluntarily participating in the trial and signing the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with allergic predisposition; (2) Patients with severe cardiac, hepatic, or renal insufficiency or other systemic diseases; (3) Patients with psychiatric disorders or cognitive impairment who cannot cooperate with the study; (4) Patients currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nausea and vomiting;Bone marrow suppression; | — |
Secondary
| Measure | Time frame |
|---|---|
| Karnofsky Performance Score,KPS;Tumor markers;Abnormal liver function;"Functional Assessment of Cancer Therapy - Breast (FACT-B) Quality of Life Score;Improvement of TCM syndromes;Tumor markers; | — |
Countries
China
Contacts
Public ContactYanwei Wang
The Second Hospital of Lanzhou University
Outcome results
None listed